Archives
tFUS Damps Post-Stroke Neuroinflammation via Nespas/miR-383-
2026-05-16
Transcranial Focused Ultrasound Modulates Neuroinflammation After Stroke via the Nespas/miR-383-3p/SHP2 Pathway
Study Background and Research Question
Ischemic stroke is a leading cause of long-term disability and mortality worldwide. Its pathogenesis is marked not only by the acute disruption of cerebral blood flow but also by secondary neuroinflammation, which exacerbates tissue damage and impairs recovery. Microglial activation and the resulting release of pro-inflammatory mediators, particularly through the NLRP3 inflammasome, have been implicated in this process, making them critical targets for therapeutic intervention (paper). However, the molecular mechanisms enabling noninvasive neuromodulation strategies to modulate these pathways remain incompletely understood. Transcranial focused ultrasound stimulation (tFUS) has recently emerged as a noninvasive method with the potential to modulate neuroinflammation and promote neurological recovery. The central research question addressed by Hong et al. (2025) is: How does tFUS exert its neuroprotective effects after ischemic stroke, and what are the underlying molecular mechanisms—specifically regarding microglial NLRP3 inflammasome activation and the role of the SHP2 signaling pathway (paper)?Key Innovation from the Reference Study
The principal innovation of this study is the identification of a novel regulatory axis—Nespas/miR-383-3p/SHP2—through which tFUS attenuates NLRP3-mediated neuroinflammation after ischemic stroke (paper). This is the first report to mechanistically link tFUS-induced upregulation of Nespas, a long non-coding RNA (lncRNA), with downstream suppression of the NLRP3 inflammasome via modulation of miR-383-3p and SHP2 (Src homology 2 domain-containing phosphatase 2). The study demonstrates that manipulating this axis can modulate the neuroprotective efficacy of tFUS, thus providing a molecular framework for targeted intervention in post-stroke neuroinflammation.Methods and Experimental Design Insights
Hong et al. employed a rat model of transient middle cerebral artery occlusion (MCAO) to mimic ischemic stroke. Low-intensity tFUS was applied to the ischemic hemisphere 24 hours post-occlusion, with daily sessions for seven days. Neurological outcomes were assessed via standardized neurobehavioral scoring. Tissue-level effects were characterized using western blotting, immunofluorescence, and quantitative real-time PCR to quantify NLRP3, Nespas, SHP2, and related pathway components in both brain tissue and BV2 microglial cells subjected to oxygen-glucose deprivation/reperfusion (OGD/R) injury (paper). Mechanistic insight was gained through RNA sequencing and transient transfection experiments targeting Nespas and SHP2. Loss- and gain-of-function approaches established causal relationships between pathway components and tFUS effects. Notably, SHP2 function was manipulated via selective inhibition and genetic silencing to dissect its role within the Nespas/miR-383-3p/SHP2 axis.Protocol Parameters
- animal model of ischemic stroke | Rat MCAO (middle cerebral artery occlusion) | neuroinflammation and neuroprotection studies | recapitulates key features of human ischemic stroke | paper
- tFUS application | Low-intensity, 24 h post-MCAO, daily ×7 days | neuromodulation of inflamed hemisphere | mirrors translational time window for acute intervention | paper
- in vitro OGD/R model | BV2 microglial cells | mechanistic dissection of cellular pathways | enables targeted manipulation of Nespas/miR-383-3p/SHP2 | paper
- SHP2 inhibition | selective inhibitor, dose per literature | mechanistic validation of SHP2 role | confirms SHP2 as a functional node in pathway | workflow_recommendation
Core Findings and Why They Matter
The study’s central findings are:- tFUS improves neurological outcomes post-stroke, as evidenced by reduced infarct size and improved behavioral scores (paper).
- tFUS suppresses NLRP3 inflammasome activation in both brain tissue and microglia, linking neuromodulation to inflammation resolution.
- Nespas expression is upregulated by tFUS, while its silencing reverses beneficial effects and increases NLRP3 activation, indicating that Nespas is upstream in the neuroprotective axis.
- Nespas positively regulates SHP2; SHP2 inhibition or knockdown amplifies NLRP3 activation and negates tFUS benefits, confirming that SHP2 acts downstream in this pathway.
- Mechanistic in vitro experiments show that Nespas acts via miR-383-3p to modulate SHP2, ultimately dampening microglial NLRP3 activation and inflammatory cytokine production.
Comparison with Existing Internal Articles
Recent internal resources echo and contextualize these findings:- "tFUS Modulates NLRP3 Neuroinflammation via the Nespas/miR-383-3p/SHP2 Axis" and "tFUS Attenuates Post-Stroke Neuroinflammation via SHP2 Pathway" both confirm the critical role of the SHP2 pathway in tFUS-mediated neuroprotection. These analyses synthesize molecular and translational perspectives, reinforcing the mechanistic relevance identified in the present reference study.
- Articles such as "NSC 87877: Strategic Shp2 Inhibition for Neuroinflammation Research" and "NSC 87877: Precision Shp2 Inhibitor for Neuroinflammation Assays" highlight the utility of selective Shp2 inhibitors in dissecting the contribution of this phosphatase to neuroinflammatory processes, providing a translational toolkit that aligns with the experimental strategies used in the reference study.
Limitations and Transferability
Despite the robust experimental design, several limitations warrant consideration:- Species translation: The study utilizes rat MCAO models and BV2 microglial cell lines, which, while informative, may not fully recapitulate human pathophysiology (paper).
- Temporal window: tFUS was administered 24 hours post-stroke, a timeframe that may not be feasible in all clinical scenarios. The durability and optimal timing of intervention remain to be established.
- Pathway specificity: While the Nespas/miR-383-3p/SHP2 axis is implicated, broader transcriptomic and proteomic changes resulting from tFUS remain to be mapped. Off-target effects or parallel pathways could modulate outcomes.
- Pharmacological tool limitations: SHP2 inhibition in vivo can have pleiotropic effects; thus, interpretation of pathway dissection should consider potential non-specific consequences.